Perrigo Says Rx Generic Pursuits Will Strengthen OTC Private Label Business
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's move into prescription generics will further enhance its market-leading position in private label over-the-counter and Rx-to-OTC switch drugs, the firm claims
You may also be interested in...
Cough/Cold Sales Shortfall Has Perrigo Looking To Smoking Cessation
Perrigo expects nicotine replacement gum product revenue to compensate in part for lagging winter cough/cold sales in the second half of its fiscal year
Rx Or OTC Statins May Be Springboard For Perrigo Generics Unit
Perrigo is looking into developing its own line of private label statin drugs
March of the generic loratadines
FDA approves a quartet of generic loratadine syrup products Aug. 20. Perrigo gets the nod for a 10 mg/10 ml strength, further building the firm's market-leading generic loratadine franchise 1("The Tan Sheet" Aug. 16, 2004, p. 4). Morton Grove, Ranbaxy and Taro receive approval for 5 mg/mL strength...